1. Home
  2. GALT vs GRABW Comparison

GALT vs GRABW Comparison

Compare GALT & GRABW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

HOLD

Current Price

$4.12

Market Cap

261.1M

Sector

Health Care

ML Signal

HOLD

Logo Grab Holdings Limited Warrant

GRABW

Grab Holdings Limited Warrant

N/A

Current Price

$0.29

Market Cap

0.0

ML Signal

N/A

Company Overview

Basic Information
Metric
GALT
GRABW
Founded
2000
2012
Country
United States
Singapore
Employees
N/A
11267
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
261.1M
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GALT
GRABW
Price
$4.12
$0.29
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
812.7K
54.7K
Earning Date
11-14-2025
02-21-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,686,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.65
52 Week Low
$0.94
$0.15
52 Week High
$7.13
$0.59

Technical Indicators

Market Signals
Indicator
GALT
GRABW
Relative Strength Index (RSI) 36.28 37.58
Support Level $3.90 $0.29
Resistance Level $4.19 $0.32
Average True Range (ATR) 0.54 0.04
MACD -0.19 -0.00
Stochastic Oscillator 17.22 32.53

Price Performance

Historical Comparison
GALT
GRABW

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

About GRABW Grab Holdings Limited Warrant

Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore, Indonesia, and Malaysia contributed more than 70% of revenue in 2024. Grab's main competitors in Southeast Asia are Line Man and Goto. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.

Share on Social Networks: